全文获取类型
收费全文 | 11475篇 |
免费 | 732篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 95篇 |
儿科学 | 217篇 |
妇产科学 | 217篇 |
基础医学 | 1506篇 |
口腔科学 | 247篇 |
临床医学 | 1473篇 |
内科学 | 2100篇 |
皮肤病学 | 73篇 |
神经病学 | 1062篇 |
特种医学 | 374篇 |
外科学 | 1577篇 |
综合类 | 127篇 |
一般理论 | 12篇 |
预防医学 | 1332篇 |
眼科学 | 217篇 |
药学 | 926篇 |
中国医学 | 13篇 |
肿瘤学 | 665篇 |
出版年
2023年 | 68篇 |
2022年 | 36篇 |
2021年 | 184篇 |
2020年 | 160篇 |
2019年 | 220篇 |
2018年 | 284篇 |
2017年 | 204篇 |
2016年 | 212篇 |
2015年 | 275篇 |
2014年 | 377篇 |
2013年 | 553篇 |
2012年 | 880篇 |
2011年 | 930篇 |
2010年 | 510篇 |
2009年 | 514篇 |
2008年 | 842篇 |
2007年 | 874篇 |
2006年 | 867篇 |
2005年 | 880篇 |
2004年 | 868篇 |
2003年 | 754篇 |
2002年 | 732篇 |
2001年 | 93篇 |
2000年 | 69篇 |
1999年 | 84篇 |
1998年 | 115篇 |
1997年 | 85篇 |
1996年 | 64篇 |
1995年 | 60篇 |
1994年 | 55篇 |
1993年 | 53篇 |
1992年 | 31篇 |
1991年 | 22篇 |
1990年 | 24篇 |
1989年 | 26篇 |
1988年 | 18篇 |
1987年 | 22篇 |
1986年 | 19篇 |
1985年 | 23篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 19篇 |
1981年 | 20篇 |
1980年 | 16篇 |
1979年 | 4篇 |
1978年 | 10篇 |
1977年 | 8篇 |
1976年 | 10篇 |
1975年 | 5篇 |
1972年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
Matthew C. Phillips Laura Sarff Josh Banerjee Chase Coffey Paul Holtom Steve Meurer Noah Wald-Dickler Brad Spellberg 《Journal of medical virology》2022,94(1):318-326
When hospitals first encountered coronavirus disease 2019 (COVID-19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single-center studies began to report declining mortality of patients with COVID-19. To evaluate the effect of COVID-19 on hospital-based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID-19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all-cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID-19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure. 相似文献
4.
5.
Shane R. Stecklein Simona F. Shaitelman Gildy V. Babiera Isabelle Bedrosian Dalliah M. Black Matthew T. Ballo Isadora Arzu Eric A. Strom Valerie K. Reed Tomas Dvorak Benjamin D. Smith Wendy A. Woodward Karen E. Hoffman Pamela J. Schlembach Steve M. Kirsner Christopher L. Nelson Jinzhong Yang William Guerra Elizabeth S. Bloom 《Practical radiation oncology》2019,9(1):e4-e13
Purpose
This study aimed to prospectively characterize toxicity and cosmesis after accelerated partial breast irradiation (APBI) with 3-dimensional conformal radiation therapy (CRT) or single-entry, multilumen, intracavitary brachytherapy.Methods and materials
A total of 281 patients with pTis, pT1N0, or pT2N0 (≤3.0 cm) breast cancer treated with segmental mastectomy were prospectively enrolled from December 2008 through August 2014. APBI was delivered using 3-dimensional CRT (n = 29) or with SAVI (n = 176), Contura (n = 56), or MammoSite (n = 20) brachytherapy catheters. Patients were evaluated at protocol-specified intervals, at which time the radiation oncologist scored cosmetic outcome, toxicities, and recurrence status using a standardized template.Results
The median follow-up time is 41 months. Grade 1 seroma and fibrosis were more common with brachytherapy than with 3-dimensional CRT (50.4% vs 3.4% for seroma; P < .0001 and 66.3% vs 44.8% for fibrosis; P = .02), but grade 1 edema was more common with 3-dimensional CRT than with brachytherapy (17.2% vs 5.6%; P = .04). Grade 2 to 3 pain was more common with 3-dimensional CRT (17.2% vs 5.2%; P = .03). Actuarial 5-year rates of fair or poor radiation oncologist-reported cosmetic outcome were 9% for 3-dimensional CRT and 24% for brachytherapy (P = .13). Brachytherapy was significantly associated with inferior cosmesis on mixed model analysis (P = .003). Significant predictors of reduced risk of adverse cosmetic outcome after brachytherapy were D0.1cc (skin) ≤102%, minimum skin distance >5.1 mm, dose homogeneity index >0.54, and volume of nonconformance ≤0.89 cc. The 5-year ipsilateral breast recurrence was 4.3% for brachytherapy and 4.2% for 3-dimensional CRT APBI patients (P = .95).Conclusions
Brachytherapy APBI is associated with higher rates of grade 1 fibrosis and seroma than 3-dimensional CRT but lower rates of grade 1 edema and grade 2 to 3 pain than 3-dimensional CRT. Rates of radiation oncologist-reported fair or poor cosmetic outcomes are higher with brachytherapy. We identified dosimetric parameters that predict reduced risk of adverse cosmetic outcome after brachytherapy-based APBI. Ipsilateral breast recurrence was equivalent for brachytherapy and 3-dimensional CRT. 相似文献6.
7.
8.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
9.
10.